Literature DB >> 23380736

Postembolization syndrome after hepatic transarterial chemoembolization: effect of prophylactic steroids on postprocedure medication requirements.

Matthew J Kogut1, Rush H Chewning, William P Harris, Daniel S Hippe, Siddharth A Padia.   

Abstract

PURPOSE: To evaluate the impact of prophylactic use of dexamethasone and scopolamine on analgesic and antiemetic agent requirements after transarterial chemoembolization.
MATERIALS AND METHODS: A total of 148 patients underwent 316 rounds of chemoembolization for hepatocellular carcinoma at a single institution over a 17-month period. Patient charts were retrospectively reviewed for demographic data, procedural technique, and use of analgesic and antiemetic medications. Patients were grouped into three categories: group A received steroid prophylaxis before and after the procedure, group B received steroid prophylaxis before the procedure only, and group C received no steroid prophylaxis.
RESULTS: Analysis was performed on 125 patients undergoing 252 procedures. Demographics were similar among groups. Overall, 86 (68.8%) were male, and mean age was 62 years (range, 39-82 y). Ninety-one patients (75%) had Child-Pugh class A cirrhosis and 25% had Child-Pugh class B cirrhosis. Dexamethasone was not significantly associated with decreased analgesic agent use (P = .6). Group A patients used significantly fewer antiemetic agents (Δ = 0.89; P = .007) compared with group C. A transdermal scopolamine patch was not associated with reduced use of antiemetic agents (P = .3). Age was inversely associated with analgesic (P <.001) and antiemetic agent use (P = .004). Men received significantly fewer antiemetic agents than women (P = .002), whereas there was no significant difference in analgesic agent use (P = .7).
CONCLUSIONS: The use of steroids did not affect analgesic agent use and had a minor effect on antiemetic requirements. The use of a scopolamine patch was not associated with reduced antiemetic agent use.
Copyright © 2013 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23380736     DOI: 10.1016/j.jvir.2012.11.019

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  8 in total

Review 1.  Prevention and management of infectious complications of percutaneous interventions.

Authors:  Steven Y Huang; Asher Philip; Michael D Richter; Sanjay Gupta; Mark L Lessne; Charles Y Kim
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

2.  Prevention of post-embolization syndrome after transarterial chemoembolization for hepatocellular carcinoma-is prophylactic dexamethasone useful, or not?

Authors:  Toru Ishikawa
Journal:  Hepatobiliary Surg Nutr       Date:  2018-06       Impact factor: 7.293

3.  Hydromorphone Hydrochloride Use During Various Interventional Radiology Procedures-Pain Control and Adverse Events: A Case Series Audit Analysis.

Authors:  Thea Moran; Amit Prabhakar; James H Diaz; Alan David Kaye
Journal:  Pain Ther       Date:  2017-10-27

4.  Identifying predictors and evaluating the role of steroids in the prevention of post-embolization syndrome after transarterial chemoembolization and bland embolization.

Authors:  Rohit Agrawal; Muhammad Majeed; Sheeba-Ba Aqeel; Yuchen Wang; Zohaib Haque; Yazan Abu Omar; Shristi Banskota Upadhyay; Thomas Gast; Bashar M Attar; Seema Gandhi
Journal:  Ann Gastroenterol       Date:  2020-12-12

5.  Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis.

Authors:  Haohao Lu; Chuansheng Zheng; Bin Liang; Bin Xiong
Journal:  BMC Gastroenterol       Date:  2021-06-11       Impact factor: 3.067

6.  Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer.

Authors:  Li-Fang Bian; Xue-Hong Zhao; Bei-Lei Gao; Sheng Zhang; Guo-Mei Ge; Dong-Di Zhan; Ting-Ting Ye; Yan Zheng
Journal:  World J Gastroenterol       Date:  2020-08-14       Impact factor: 5.742

7.  Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.

Authors:  Jinpeng Li; Congcong Shi; Jutian Shi; Jinlong Song; Nan Wang
Journal:  Medicine (Baltimore)       Date:  2021-11-05       Impact factor: 1.817

8.  Dexamethasone prevents TACE-induced adverse events: A meta-analysis.

Authors:  Lei Chang; Wei Wang; Nanhui Jiang; Fengying Rao; Cheng Gong; Ping Wu; Jian Yang; Zhisu Liu; Tao Guo
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.